MMJ Recs

NOVEMBER 30, 2023

While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. In recent years, there has been growing interest in exploring alternative treatment options, and one that has gained attention is medical marijuana (MMJ).

Epilepsy 105

Epilepsy Treatment Patients Strains 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

NORML

APRIL 30, 2020

CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. .”

Chronic Pain 346

Chronic Pain Clinical Trials Data Patients 346

NORML

MARCH 30, 2020

They reported “circumstantial evidence” suggesting that CBD may possess antiviral acticity in a limited number of conditions, specifically in the treatment of hepatitis C and Karposi sarcoma. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 300

CBD Clinical Trials Data Treatment 300

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. For more information, visit the company’s website or download their investor presentation. MedXtractor Corp.’s Looking Ahead.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Medical Marijuana Program Connection

FEBRUARY 27, 2023

The cannabis oil will be used as a part of the Company‘s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL. Read More

Clinical Trials 52

Clinical Trials Oil CBD Treatment 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 194

Clinical Trials Chronic Pain Data Treatment 194

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures.

Clinical Trials 91

Clinical Trials Research and Development Data Collective 91

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960). Learn more about PAOG at www.paogroupinc.com.

Treatment 52

Treatment Research and Development CBD eCommerce 52

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

CannaMD

JUNE 2, 2021

Another noteworthy finding of the study was the revelation that more than half of patients using marijuana to treat symptoms of Parkinson’s had not been provided with any information or recommendations on dosage, cannabis type, or frequency of use.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. One study from the Journal of Clinical Oncology examined the efficacy of cannabinoids in appetite stimulation.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Medicinal Marijuana Association

FEBRUARY 11, 2024

The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community. Potential for enhanced treatment outcomes with cannabis use. Improves optic nerve blood flow and protects retinal cells.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

The Cannigma

MARCH 18, 2021

Taken together, the lack of guidance and lack of information about what treatments patients are taking, may underlie “inconsistencies in both use and reported effectiveness,” the researchers stated. Where do Parkinson’s patients get information about cannabis? Here are the most interesting statistics from the survey.

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Cannabis Law Report

AUGUST 10, 2022

The lead investigators are Jacobo Mintzer , MD, MBA, Brigid Reynolds , ANP-BC, and the Alzheimer’s Clinical Trial Consortium (ACTC).The ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. MediPharm Labs Corp. Logo (CNW Group/MediPharm Labs Corp.). Management Commentary.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. For more information, visit filament.health. Over the next several years, the psychedelics industry is expected to grow at a compound annual growth rate of 16.3

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

MAY 28, 2022

For more information, visit huschblackwell.com. We have been following the research and development of these medicines for psychiatric conditions such as PTSD and treatment-resistant depression. How does Husch Blackwell intend to assist or guide innovators in the psychedelics industry? Read full article at.

Research and Development 52

Research and Development Therapy Clinical Trials Legalization 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Physicians should consider these aspects when advising their patients about treatment with medicinal cannabis. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

OCTOBER 13, 2021

The PCT filing also includes support for future research programs respecting various systems which seek to minimize negative side effects in psychedelic psychotherapy patients, methods that enable lower and sub-psychedelic doses without impacting treatment efficacy and increasing the long-term efficacy of psychedelic sessions. About Cybin.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes. of prescriptions were for sleep disorders. Read their full article at.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

APRIL 2, 2022

a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil (the “Ibogaine Group”). For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52